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CORD BLOOD (CB) APGAR SCORE IS PREDICTIVE OF NEUTROPHIL
ENGRAFTMENT AND GRAFT FAILURE PROBABILITIES FOR PLASMA
DEPLETED/REDUCED CB PRODUCTS
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Nucleated cell (NC), CD341 cell (CD34), and colony forming unit
(CFU) doses have been proposed to measure CB potency - important
for engraftment potential prediction and transplantation product selec-
tion.ThoughTNCiswidelyused forCBselection, its predictive value is
not as robust as the progenitor cell measurements. CFU andCD34 suf-
fer from high inter-laboratory coefficient of variance (CV) - decreasing
the clinical utility as potency measures. Recently, the Duke Group pro-
posed a CB APGAR scoring system composed of (a) a Pre-Cryopre-
served Score (PCS) reflecting pre-freeze CFU, CD34, NC, and CB
collected volume, aswell as a (b)Composite Score (CS)which combines
the PCS score with post-thaw NC, CD34, CFU and mononuclear cell
dose. Based on single, myeloablative and first (SMF) transplants of
largely pediatric patients performed at Duke and using mostly red cell
reduced (RCR)CB, the PCS andCS scores were shown to be predictive
of graft failure, neutrophil and platelet engraftment. With CIBMTR-
auditedoutcomedataof transplantedCBproducts fromamulti-national
CBbank,we sought to validate theCBAPGARsystemonapatient pop-
ulationwithmostly adults, heavy representationofminority and interna-
tional patients, and on both SMF transplants, and all transplants (All)
using plasma depleted/reduced (PDR) CB products. The PCS and CS
table below shows the day 42 neutrophil engraftment cumulative inci-
dence (ANC500) and graft failure probability (GF) comparisons of the
Duke data with PDR transplants for both SMF and All transplants.
For each of the PCS and CS strata compared, ANC500 and GF ap-
peared to be similar among theDuke SMF, StemCyte SMF and All co-
horts.We conclude that theCBAPGARscore, especially the PCS, is an
easy-to-use and reproducible potencymeasurement forCB selection by
transplant centers that is highly predictive of ANC500 engraftment and
GF for (1) RCRaswell as PDRCB, (2) formostly pediatric patient pop-
ulationaswell as formixedpopulationsof adults andchildren, and (3) for
minority and international patients.Whether themethod canbe applied
to double, non-myeloablative and repeat CB transplants remains to be
seen.Lastly, for the samePCSorCSstrata,PDRCBappear tohave sim-
ilar engraftment and GF probabilities as RCRCB; therefore, the Duke
CB APGAR is applicable to CB products with or without RBC reduc-
tion and reflects potencyofCBproducts processed and storedby various
methods at different CB banks.
Table 1. ANC 500 Engraftment Cumulative Incidence & Graft
Failure Probabilities
ANC 500 Duke SMF PDR SMF PDR AllPCS$7.75 93% (86-100%) 100±18% 83±19%
PCS<7.75 75% (69-81%) 78±9% 76±4%
HR 2.44 (1.78 - 3.59) 2.43 (0.85 - 6.95) 1.92 (0.78 - 4.68)
CS$13.5 90% (84 - 95%) 94±14% 84±11%
CS<13.5 69% (61 - 78%) 68±12% 77±6%
HR 2.31 (1.73 - 3.08) 1.54 (0.73 - 3.26) 1.19 (0.78 - 1.82)Graft Failure
ProbabilityDuke SMF PDR SMF PDR AllPCS$7.75 7% (3-17%) 0±18% 17±19%
PCS$5.5 & <7.75 19% (12-30%) 15±14% 18±10%
PCS$4.25 & <5.5 26% (16-39%) 6±13% 14±9%
PCS<4.25 32% (22-45%) 38±12% 29±5%50
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Background:Tregs are attractive candidates for clinical modulation
of excessive immune responses. In SCT mouse models, the adoptive
transfer of purified natural Tregs has been shown to prevent GvHD,
while sparing a significant GvL effect. Tregs’ suppressor function
has been demonstrated to be critically dependent on IL-2, therefore
cyA significantly reduces the function of allostimulated Tregs.
Aim: To address the role of Tregs in human SCT, we focused on
a calcineurin inhibitor-free GvHD prophylaxis. We tested this hy-
pothesis in haploidentical peripheral blood stem cells SCT without
any in-vitro manipulation.
Patients and Methods: Since 2007, 68 pts underwent allo-SCT for
AML (43), ALL (9),MDS (3),MPD (4), NHL (4) orHD (5).Median
age was 48 years (range 14-69). At SCT all but 8 pts were in advanced
phase. Conditioning included Treosulfan (14 g/m2 for 3), Fludara
(30 mg/m2 for 5) and an in-vivo T and B-cell depletion, by ATG-
Fresenius (10 mg/kg for 3) and Mabthera (a single 500 mg dose).
All pts received allogeneic PBSC from an HLA-haploidentical
related donor without any in-vitro positive selection. GvHDprophy-
laxis consisted of Rapamycin (target level 8-15 ng/ml, till day 160)
and MMF (15 mg/kg tid till day 130).
Results: All pts but 3 had neutrophil engraftment. CI of grade 2-4,
grade 3-4 aGvHD and cGvHD were 22%, 11% and 26%. 100 days
TRM and relapse incidence at 1 year were 17% and 44%. Projected
OS at 1 year is 39%. Immunoreconstitution was fast and sustained
with amedian 220 circulatingCD31cells/mLonday130.Wedetected
high levels of CD41CD251CD127- FOXP31 Tregs (up to 30% of
circulating CD41 T lymphocytes) on day 130. These cells were able
to suppress in vitroproliferationof autologous effector cells.Thisobser-
vation was further reinforced at a molecular level.We applied a quanti-
tative RT-PCR based methylation assay that enables a specific and
sensitive determination of T regs numbers by measuring demethylated
FOXP3atT reg specific demethyleted region (TSDR).Anexpansionof
cells carrying FOXP3 demethylation was evident in our pts, but not in
a control group of pts receiving mismatched SCT and cyclosporine.
Conclusions: Rapamycin-Mycophenolate-ATG are effective as
GvHD prophylaxis in unmanipulated haploidentical peripheral SCT
andare associatedwith an earlyT-cell immunoreconstitution character-
ized by the in-vivo expansion of Tregs. Further studies are warranted to
gain insight correlations between Tregs expansion and SCT outcome.
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Aim: Calculation of the 8/8 (HLA-A, B, C, DRB1) high-resolution
(HR) match rate using real patient unrelated donor (URD) searches
presents a biased sample for reasons including access to treatment, fi-
nancial barriers and incomplete donor testing. A study was designed
to estimate the truematch rate forCaucasian (CAU),Hispanic (HIS),
Asian/Pacific Islander (API), and African American (AFA) groups,
representing the four largest race groups in the US population.
Methods: 1344 URD searches were performed for pseudopatients
(PP) who were randomly selected, previously HR tested donors in
the NMDP’s Be The Match Registry (BTMR). Searches were based
on a fixed BTMR file as of January 2009. Search results from CAU,
HIS, API, and AFA PP were classified as follows:
